{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-combined-hormonal-methods/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"4153191e-d9ff-5a0c-8deb-90d8e2024b3c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 112a80f9-820f-450e-8af7-ffaf1a2b788e --><h2>Changes</h2><!-- end field 112a80f9-820f-450e-8af7-ffaf1a2b788e -->","summary":null,"htmlStringContent":"<!-- begin item df9a8e7e-e9e8-4dc5-914d-0e42c241fe3f --><!-- begin field 340c0528-cdfe-4db1-9e30-a02de1549c87 --><p><strong>January 2021 </strong>— minor update. Recommendations on switching from the progestogen-only implant to combined hormonal contraception have been updated in line with the updated Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Switching or starting methods of contraception</em>.</p><p><strong>August 2020</strong> – minor update. Adverse effects of co-cyprindiol added to Combined oral contraceptive methods risk and adverse effects. </p><p><strong>July 2020</strong> – minor update. Adverse effects of combined oral contraceptive updated in line with revised manufacturer's SPC for co-cyprindiol.</p><p><strong>March 2020</strong> – minor update. The information on how to manage incorrect use of combined hormonal contraception has been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Recommended actions after incorrect use of combined hormonal contraception.</em></p><p><strong>May 2019</strong> — minor update. Information added to the disadvantages of vaginal rings in line with SPC update - Ring breakage is more common if a woman concomitantly uses intravaginal preparations, including antimycotic, antibiotic and lubricant products. Depressed mood/depression have been added as adverse effects of the combined hormonal contraceptive pill. </p><p><strong>January 2019</strong> — reviewed. The topic has been updated to reflect the latest Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Combined hormonal contraception,</em> including information that there is no health benefit from the seven-day hormone-free interval, women can safely take fewer (or no) hormone-free intervals to avoid monthly bleeds, cramps and other symptoms, if a hormone-free interval is taken, shortening it to four days could potentially reduce the risk of pregnancy if pills, patches or rings are missed, consultations about CHC do not necessarily have to be face-to-face; online CHC provision is possible, at the first consultation, many women can safely be prescribed a one year supply of CHC instead of the current three month supply. The topic has also been updated to include the recommendations in the FSRH guideline <em>Interim FSRH guidance on incorrect use of combined hormonal contraception (December 2018)</em>.</p><!-- end field 340c0528-cdfe-4db1-9e30-a02de1549c87 --><!-- end item df9a8e7e-e9e8-4dc5-914d-0e42c241fe3f -->","topic":{"id":"605c1bb8-0483-50f0-bdbb-78319fe29a81","topicId":"aac9c264-cad6-4bdb-be6d-48707289f4de","topicName":"Contraception - combined hormonal methods","slug":"contraception-combined-hormonal-methods","lastRevised":"Last revised in January 2021","chapters":[{"id":"7cd23cd5-86d3-5fc9-ace1-c698f636b17a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d14e4195-a4a5-5c99-af9d-40d049f80564","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8fda14d-5966-56b7-b191-e19e71058589","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4153191e-d9ff-5a0c-8deb-90d8e2024b3c","slug":"changes","fullItemName":"Changes"},{"id":"2943b148-103b-57f3-ac33-95d3eda5a376","slug":"update","fullItemName":"Update"}]},{"id":"8e592c94-5796-5947-a88e-469c0fc179b9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"907b8933-351e-58d4-bd1a-3f9a0fbc5030","slug":"goals","fullItemName":"Goals"},{"id":"f11eea2c-63d3-5ea9-a92f-62884472c60d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6f8379f-6e43-57b4-ac5c-b716abed76f2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"65637fc4-798a-57f2-aed9-fbc3b121f561","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"319c6322-634e-54a4-8cbe-420321c479c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f9a0a37f-beb8-5a09-a73b-d11ec241c910","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ad2ff41f-7db1-59cc-acc9-d41c00f2c76e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b8d532b-8ead-5d51-9109-f9e8824c9c7f","slug":"where-to-get-combined-hormonal-contraception","fullItemName":"Where to get combined hormonal contraception"},{"id":"45ba6601-c636-51b8-8934-cf9340b6d88a","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"309fc425-cdee-5ea2-8d12-53e5f4a5c7bc","slug":"tailored-regimen","fullItemName":"Tailored regimen"}]},{"id":"4d23fe10-1021-588d-aa48-8e99bded21b6","fullItemName":"Management","slug":"management","subChapters":[{"id":"861b6ed8-1f56-5353-ad39-d786fa8ca178","slug":"combined-oral-contraceptive","fullItemName":"Scenario: Combined oral contraceptive"},{"id":"711eff7a-2ae7-5e48-be26-55979dd4d45e","slug":"combined-contraceptive-patch","fullItemName":"Scenario: Combined contraceptive patch"},{"id":"2ff0852b-51d2-5fea-9dd4-35c8e22860fb","slug":"combined-contraceptive-vaginal-ring","fullItemName":"Scenario: Combined contraceptive vaginal ring"}]},{"id":"5ddc2dd6-9aa6-53ed-8178-6fdd04696bc6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5aaef45b-e1b3-50ac-abcc-41b27f64d556","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c2946c85-d802-5901-a0ac-cdf3817e8f7d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ada6579b-ea7c-5a26-9270-f15e52a5357b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"aca4349d-feb2-5c02-98de-d651db1a254b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7767b31a-210c-565f-a324-c063b43fafeb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b918522-b08f-5590-a737-b3487e6db88e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"18cb03af-cf87-57a9-be06-162096046fc1","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f8fda14d-5966-56b7-b191-e19e71058589","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f68043c3-eda2-5c02-8bac-eb61a3559b75","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ca83567b-aae7-4777-8934-316916fed967 --><h3>Previous changes</h3><!-- end field ca83567b-aae7-4777-8934-316916fed967 -->","summary":null,"htmlStringContent":"<!-- begin item 8b5f8107-a936-4b9d-b4c7-02a8e7235e88 --><!-- begin field 8debfa53-8aea-4825-be05-be2754e1c6e5 --><p><strong>June 2018</strong> — minor update.<strong> </strong>Panic attacks have been added to adverse effects for people taking desogestrel. </p><p><strong>December 2017 </strong>— minor update. Added information about fetal malformations and effectiveness of hormonal contraceptives as an effect of topiramate. </p><p><strong>June 2017</strong> — minor update. Additional drug interaction added for drugs to treat hepatitis C as per update to the manufacturer's summary of characteristics <a data-hyperlink-id=\"0ab66c19-7be4-4b86-8b43-a8fe009b739e\" href=\"http://www.medicines.org.uk/emc/medicine/1899\">http://www.medicines.org.uk/emc/medicine/1899</a>.</p><p><strong>February 2017</strong> — minor update.</p><ul><li>The information on drug interactions has been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Drug Interactions with hormonal contraception</em> 2017.</li><li>Recommendations on when to start combined hormonal contraception after pregnancy, miscarriage, or termination of pregnancy have been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Contraception after pregnancy</em> 2017.</li></ul><p><strong>June to July 2016</strong> — reviewed. A literature search was conducted in June 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor structural changes have been made.</p><p><strong>December 2014</strong> — minor updates. An interaction between colesevelam and oral contraceptives has now been included.</p><p><strong>July 2014</strong> — two minor updates: Information on the use of the new combined oral contraceptive (COC) Zoely<sup>®</sup> has now been included and Alenvona<sup>®</sup> a new COC has been added to the list of oral contraceptives available to prescribe in the UK.</p><p><strong>March 2014</strong> — minor update. Text amended to reflect updated Faculty of Sexual and Reproductive Healthcare (FSRH) guidance <em>Combined Hormonal Contraception</em> (2012) regarding what to do if a woman has persistent vomiting or diarrhoea for more than 24 hours.</p><p><strong>March 2014 </strong>— minor update. Update to the text to reflect new guidance from Medicines and Healthcare products Regulatory Agency (MHRA) (2014) regarding St John's wort and women using hormonal contraceptives.</p><p><strong>March 2014</strong> — minor update. Update to the text regarding the MHRA review (2014) of the risk of venous thromboembolism (VTE) with combined hormonal contraception. This review confirms that the risk of VTE is small. No changes have been made to the recommendations.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>May 2013</strong> — minor update to the text to reflect advice issued by the FSRH (2013) regarding the interaction between combined hormonal contraceptives and newer antiepileptics.</p><p><strong>March 2013</strong> — minor update. The telephone number for NHS Direct has been updated.</p><p><strong>January 2013</strong> — minor update. Change to the text to reflect updated advice from the FSRH (2012) regarding the interaction between Esmya<sup>®</sup> and hormonal contraceptives.</p><p><strong>September 2012</strong> — minor update. The Black triangle status has been removed from Qlaira<sup>®</sup> tablets.</p><p><strong>February to June 2012</strong> — reviewed. A literature search was conducted in December 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomised controlled trials (RCTs) published since the last revision of the topic. No changes to clinical recommendations have been made. However, recommendations have been rewritten for clarity, and superseded guidelines and manufacturers' Summary of Product Characteristics (SPCs) have been updated accordingly.</p><p><strong>February 2012</strong> — minor update. Correction to advice on delayed application of contraceptive patch (see the section on Patch not changed or cycle started late). Issued in February 2012.</p><p><strong>June 2011</strong> — minor update. Advice from the MHRA that the risk of VTE with the drospirenone-containing COC pill (Yasmin<sup>®</sup>) may be similar to the risk for desogestrel-containing or gestodene-containing third generation COCs. Issued in June 2011.</p><p><strong>May 2011</strong> — minor update. Correction of formatting error in table on starting combined oral contraception. Issued in June 2011.</p><p><strong>May 2011</strong> — minor update. Changes to missed pill advice based on new recommendations from the FSRH (2011). </p><p><strong>May 2011</strong> — minor update. Added new evidence from a study (Parkin, 2011) that the risk of VTE associated with Yasmin<sup>®</sup> is higher than the risk of VTE with COCs containing levonorgestrel.</p><p><strong>May 2011</strong> — minor update. Prescription for the quadraphasic COC pill Qlaira<sup>®</sup> has been included along with information on how to start, use in breastfeeding women, and management of missed pills (which differs from that of other COCs). Issued in June 2011.</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. Issued in June 2011.</p><p><strong>February 2011</strong> — minor update. The FSRH (2011) no longer recommend that additional contraceptive precautions are required during or after courses of antibiotics that do not induce liver enzymes. However, additional contraceptive precautions are required if the antibiotic or illness causes vomiting or diarrhoea.</p><p><strong>November 2010 </strong>— minor update. Advice from the FSRH guideline <em>Quick starting contraception</em> (2010) has been included in this topic. </p><p><strong>September 2010</strong> — minor update. Prescriptions for the following new COC pills have been included: Rigevidon<sup>®</sup> (ethinylestradiol plus levonorgestrel), Gedarel<sup>®</sup> (ethinylesteradiol plus desogestrel), Millinette<sup>®</sup> (ethinylestradiol plus gestodene), and Triregol<sup>®</sup> (triphasic ethinylestradiol plus levonorgestrel).</p><p><strong>April 2010</strong> — minor update. Advice from the MHRA (2010) that the risk of VTE associated with Yasmin<sup>®</sup> is higher than COCs containing levonorgestrel, but lower than with COCs containing desogestrel or gestodene has been added.</p><p><strong>March 2010</strong> — minor update. Prescribing information sections updated in line with the FSRH (2010) statement on antiepileptic drugs and contraception. The Department of Health (2010) <em>Advice regarding assessment of young women aged under 24 years with abnormal vaginal </em>bleeding has also been added.</p><p><strong>February 2010</strong> — updated to include the revised <em>U</em><em>K Medical Eligibility Criteria for contraceptive use</em>, as published by the FSRH (2009).</p><p><strong>October 2009</strong> — updated to include the combined contraceptive vaginal ring, on the basis of the SPC for NuvaRing<sup>®</sup> (2012) and a FSRH, <em>New product review</em> (2009). The advice on when to remove a copper intrauterine device or a levonorgestrel-releasing intrauterine system in a woman with pelvic inflammatory disease has also been updated. Minulet<sup>®</sup> and Tri-Minulet<sup>®</sup> have been discontinued, so their prescriptions have been removed. </p><p><strong>April 2009</strong> — minor update. The SPC for Evra<sup>®</sup> transdermal patches now states that the patch releases 203 micrograms of norelgestromin and 33.9 micrograms of ethinylestradiol per 24 hours. The Description of patch section has been updated accordingly. </p><p><strong>March 2009</strong> — minor update. The 2009 QOF indicators for sexual health have been updated in the Goals and outcome measures section.</p><p><strong>February 2009</strong> — minor update. The upper age limits on the prescriptions for COC pills have been changed to 50 years. Issued March 2009.</p><p><strong>November 2008</strong> — minor update. The Black triangle status has been removed from Evra<sup>®</sup> patches.</p><p><strong>April 2008</strong> — minor update. Trinordiol has been discontinued. Prescriptions have been removed and a minor change in text has been made.</p><p><strong>April to September 2007</strong> — converted from CKS guidance to new topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2006</strong> — minor update. Information regarding orlistat and reduced efficacy of oral contraceptives has been included in Drug interactions section. Issued in July 2006.</p><p><strong>January 2006</strong> — minor update. Gynol II Jelly<sup>®</sup>, Microval<sup>®</sup> tablets and Duragel<sup>®</sup> have been discontinued and the prescriptions have been removed. The Black triangle status has been removed from Cerazette<sup>®</sup>.</p><p><strong>October 2005</strong> — updated to include the new recommendations on missed pills from the Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit (2005).</p><p><strong>April 2005</strong> — minor update. Neogest<sup>®</sup> tablets have been discontinued and the prescriptions have been removed.</p><p><strong>February 2005</strong> — updated to include prescribing advice from the Committee on Safety of Medicines (CSM) on the effect of depot medroxyprogesterone acetate contraception on bones.</p><p><strong>September 2004</strong> — updated to include the World Health Organization (WHO) Medical Eligibility Criteria relating to contraception for 2004 and recent licence changes to Cerazette<sup>®</sup>. Delfen<sup>®</sup> Contraceptive Foam is being discontinued at the end of October 2004 and the prescriptions have been removed.</p><p><strong>January 2004</strong> — reviewed. Validated in March 2004 and issued in June 2004.</p><p><strong>January 2001</strong> — rewritten. Validated in March 2001 and issued in June 2001. Guidance on emergency contraception is no longer included in the Contraception guidance but can be found as a separate CKS topic.</p><p><strong>December 1997</strong> — written.</p><!-- end field 8debfa53-8aea-4825-be05-be2754e1c6e5 --><!-- end item 8b5f8107-a936-4b9d-b4c7-02a8e7235e88 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}